Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 3;2(11):1334–1343. doi: 10.1158/2767-9764.CRC-22-0172

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors; Published by the American Association for Cancer Research

This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license.

PMC Copyright notice

Duloxetine does not alter uptake and antitumor properties of oxaliplatin. A, Influence of duloxetine (1 or 10 μmol/L) on the intracellular accumulation of oxaliplatin in colorectal cancer cell lines in vitro. Influence of duloxetine pretreatment on oxaliplatin-related body weight loss (B), tumor volume of xenografted luciferase-expressing HCT116 cells (C), OIPN as measured by VFH test (D), levels of total platinum in tumor samples (E), and DRG neurons (F) after completion of a 3-week treatment regimen. Bars and symbols represent mean ± SD. Details of the treatment and analysis are described in the Materials and Methods section (n = 7–9). *, P < 0.05 versus vehicle control (C), versus oxaliplatin alone (D, F). NS, not statistically significant.